The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and ...